Variety of eligible individuals: CDEC mentioned the uncertainty in the amount of individuals with moderately severe to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people that are categorized as possessing mi